

OTCQB Certification

I, Anthony Squeglia, Chief Financial Office of Boston Therapeutics, Inc. ("the Company"), certify that:

a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (check one):

- ☐ Company is registered under Section 12(g) of the Exchange Act
- ☐ Company is relying on Exchange Act Rule 12g3-2(b)
- ☐ Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
- ☐ Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
- ☒ Company is reporting under Section 15(d) of the Exchange Act.
- ☐ Other (describe) _____

b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.

c. The Company Profile displayed on www.otcmarkets.com is current and complete as of [must be latest practicable date] and includes the total shares outstanding, authorized, and in the public float as of that date.

d. The following is a complete list of attorney(s) and law firm(s) who advised or assisted in the preparation of the Company's most recent annual report, including in-house counsel: (If no attorney assisted in putting together the disclosure, indicate the person or persons who prepared the disclosure and their relationship to the company.)

Barry I. Grossman, Esq.
Lawrence A. Rosenbloom, Esq.
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, New York 10105

e. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, during the period from the Company's prior fiscal year end to the date of this OTCQB Certification, to provide investor relations services, public relations services, or other related services to the Company including promotion of the Company or its securities:

Dian Griesel, Inc.
PO Box 302
Washington Depot, CT 06794

Stonegate Securities
8201 Preston Road
Suite 325
Dallas, TX 75225


f. Listed below are the names, legal addresses and % of shares owned by all Officers, Directors and Control Persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities). If any of the beneficial shareholders are corporate shareholders, the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders must also be included.

Name	Address (City and State only)	% Shares Owned
See attached		

Date: April 15, 2015

Name of Certifying CEO or CFO: Anthony Squeglia

Title: Chief Financial Officer

Signature: 
(Digital Signatures should appear as "/s/ [OFFICER NAME]")

OFFICERS, DIRECTORS AND CONTROL PERSONS

	Number of Shares	Percent (1)
David Platt (2)**	8,575,985 (3)	21.9% (3)
Kenneth A. Tassey, Jr. 226 Karatzas Avenue #309 Manchester, NH 03108	3,043,450	7.9%
Jonathan Rome 50 Tice Boulevard Suite A35 Woodcliff Lake, NJ 07677	4,383,000 (4)	10.5% (4)
Offer Binder Via Armand Fedeli 121 Perugia PG 06132 Italy	2,000,000	5.2%
Harold Solomon Parnes 1525 Voorhies Avenue Brooklyn, NY 11235	2,020,000	5.2%
Advance Pharmaceutical Company Ltd.(5) Rm A 2- 3F, Dai Fu Street Tai Po Industrial Est. Tai Po, New Territories, Hong Kong	1,823,800 (5)	4.7% (5)
CJY Holdings Limited 7B Jonsim Place 288 Queens Road East Wanchai, Hong Kong	10,749,980 (6)	25.5% (6)
Idan Sahar 12 Nissim Aloni Tel Aviv, Israel	1,999,996 (7)	5.1% (7)
Anthony Squeglia(2)**	934,350(8)	2.4% (8)
Dale H. Conaway(2)**	135,100(9)	*
Rom E. Eliaz(2)**	76,100 (10)	*
Henry J. Esber(2)**	241,000(11)	*
S. Colin Neill(2)**	59,100 (12)	*
Alan M. Hoberman(2)**	5,000	*
Conroy Chi-Heng Cheng(2)**	1,823,800(13)	4.7% (13)
All Officers and Directors as a Group (8 persons)	11,850,435	28.9%

* Less than 1%

** Directors and Officers

- 1) Except as expressly stated, the percentages in the table are based on 38,597,008 shares of common stock outstanding as April 14, 2015
- (2) The business address for these individuals is 1750 Elm Street, Suite 103, Manchester, NH 03104.
- (3) Includes 520,000 shares owned by Dr. Platt's wife and 500,000 shares issuable pursuant to outstanding stock options currently exercisable. Excludes 20,000 shares held by Dr. Platt's daughter as to which Dr. Platt disclaims beneficial ownership. Excludes 20,000 shares held by Dr. Platt's son as to which Dr. Platt disclaims beneficial ownership.

- (4) Includes 2,500,000 shares issuable pursuant to an outstanding stock option currently exercisable. Includes 625,000 shares issuable pursuant to an outstanding warrant to purchase common stock currently exercisable.
- (5) Consists of 1,799,800 shares owned by SUGARDOWN Co., LTD., a wholly-owned subsidiary of Advance Pharmaceutical Company Ltd. Conroy Chi-Heng Cheng, a director of Boston Therapeutics, Inc., exercises voting and investment control over these securities. Includes 24,000 shares issuable pursuant to an outstanding stock option currently exercisable.
- (6) Includes 3,583,320 shares issuable pursuant to outstanding warrants to purchase common stock currently exercisable. Cheng Chi Him exercises voting and investment control over these securities.
- (7) Includes 666,664 shares issuable pursuant to outstanding warrants to purchase common stock currently exercisable.
- (8) Includes 750,000 shares issuable pursuant to outstanding stock options currently exercisable. Includes 50,000 shares issuable pursuant to an outstanding warrant to purchase common stock currently exercisable. Includes 6,000 shares owned by Mr. Squeglia's wife. Excludes 10,000 shares owned, 5,000 shares issuable pursuant to an outstanding warrant to purchase common stock held by Mr. Squeglia's son as to which Mr. Squeglia disclaims beneficial ownership. Excludes 75,000 shares issuable pursuant to an outstanding stock option currently exercisable held by Mr. Squeglia's son as to which Mr. Squeglia disclaims beneficial ownership.
- (9) Includes 133,000 shares issuable pursuant to outstanding stock options currently exercisable.
- (10) Includes 76,000 shares issuable pursuant to outstanding stock options currently exercisable.
- (11) Includes 228,000 shares issuable pursuant to outstanding stock options currently exercisable.
- (12) Includes 59,000 shares issuable pursuant to an outstanding stock option currently exercisable.
- (13) Consists of 1,799,800 shares owned by SUGARDOWN Co., LTD., a wholly-owned subsidiary of Advance Pharmaceutical Company Ltd. Conroy Chi-Heng Cheng exercises voting and investment control over these securities. Includes 24,000 shares issuable pursuant to an outstanding stock option currently exercisable.